PreveCeutical Medical (PREV) AI Stock Analysis

• Market Cap: C$11.74M
• Dividend Yield: N/A
• Average Volume (3M): 143.42K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.27
• Revenue Growth: N/A
• EPS Growth: -120.00%
• Country: CA
• Employees: 7
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): >-0.01
• Shares Outstanding: 586,811,950
• 10 Day Avg. Volume: 276,937
• 30 Day Avg. Volume: 143,419
• PEG Ratio: 114.24
• Price to Book (P/B): -2.02
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -31.30
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 42 Neutral
• Price Target: C$0.02 ▲(20.00% Upside)

The score is driven down primarily by weak financial performance—no revenue, widening losses, cash burn—and a stressed balance sheet with negative equity and notable leverage. Technicals add downside pressure as the stock trades below key moving averages with negative MACD. Corporate events provide some offset via strategic restructuring and new financing, but they do not fully mitigate the underlying funding and execution risks.

Positive Factors

Strategic focus and near-term liquidity

Completion of the BioGene spin-off and a private placement provides structural benefits: it narrows management focus onto core drug-development assets and injects cash to fund operations. This reduces immediate insolvency risk and gives months to execute on milestones and de-risk programs.

Lean operating structure

A very small headcount implies low fixed overhead and operational flexibility. For a pre-revenue biotech, lean staffing helps extend runway per financing round, allows management to allocate capital selectively to priority programs, and supports partnerships for execution without heavy fixed costs.

Improving free cash flow trend

Although free cash flow remains negative, the TTM improvement versus the prior period signals better cash management or timing of expenditures. If sustained, this trend can materially extend runway and reduce frequency of dilutive financings, improving long-term execution prospects.

Negative Factors

No revenue and widening losses

The company has no reported revenue while losses have re-accelerated. Persistent negative operating results force reliance on capital markets or partners to fund development. Without commercial revenue or clear near-term monetization, sustaining R&D and trial activities is intrinsically risky over the medium term.

Highly stressed balance sheet

Deeply negative equity and high debt relative to a tiny asset base materially limit financial flexibility. This condition increases refinancing and covenant risk, narrows options for non-dilutive funding, and elevates the probability that future capital needs will force dilutive financings or asset sales.

Reliance on external capital

The business model remains dependent on periodic financings to support operations. For a pre-revenue biotech, continuous external funding raises dilution and execution risk; success hinges on delivering program milestones or securing partnerships that convert R&D into sustainable cash flow.

PreveCeutical Medical Business Overview & Revenue Model

Company Description

PreveCeutical Medical Inc., a health sciences company, engages in the development of options for preventive and curative therapies utilizing organic and nature identical products. Its pipeline products include Cannabinoid Sol-Gel Delivery, a cannabinoid-based nose-to-brain delivery system that provides relief from various indications, including pain, inflammation, seizures, and neurological disorders; BSV Peptide Program for targeting cancer progression; Non-Addictive Analgesic for pain management; and Dual Gene Therapy for type 2 diabetes and obesity. The company also develops a range of medicinal cannabis-based products. PreveCeutical Medical Inc. is headquartered in Vancouver, Canada.

How the Company Makes Money

PreveCeutical makes money primarily through the research and development of therapeutic products, which are then licensed or sold to pharmaceutical companies or healthcare providers. The company may also generate revenue through strategic partnerships, collaborations, and possibly government or private grants supporting their innovative research. By progressing their products through clinical trials and obtaining necessary regulatory approvals, PreveCeutical can enter into commercialization agreements or secure funding from partners interested in their pipeline offerings.

PreveCeutical Medical Financial Statement Overview

Summary

PreveCeutical Medical faces significant financial challenges, with no revenue, consistent losses, high leverage, and negative cash flows. These issues highlight the company's struggle for financial stability, typical of early-stage biotech firms relying heavily on external financing while developing their product pipeline.

Income Statement

PreveCeutical Medical has shown no revenue generation for the past few years, with consistent negative gross profit and net income. The lack of revenue growth and persistent losses suggest severe profitability challenges, typical for a biotechnology firm in early stages with high R&D costs but no commercial products yet.

Balance Sheet

The company has a negative stockholders' equity, indicating insolvency, compounded by a high debt-to-equity ratio and total liabilities exceeding total assets. This high leverage poses significant financial risk, reflecting a fragile financial structure.

Cash Flow

Operating cash flow is consistently negative, and free cash flow is also in deficit. Although financing cash flow is positive, indicating external funding, the reliance on financing without generating operational cash raises sustainability concerns.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	-10.13K	-10.10K	-9.86K	-9.89K	-5.09K	-75.17K
EBITDA	-2.78M	-837.46K	-955.09K	-1.23M	-829.83K	-2.02M
Net Income	-3.08M	-1.17K	-1.27M	-1.48M	-1.73M	-3.80M
Balance Sheet
Total Assets	456.04K	225.66K	181.51K	189.14K	161.20K	302.45K
Cash, Cash Equivalents and Short-Term Investments	103.68K	59.14K	1.43K	5.62K	16.06K	156.44K
Total Debt	4.60M	4.46M	3.83M	3.23M	2.93M	3.01M
Total Liabilities	7.85M	6.86M	5.96M	4.82M	4.27M	3.91M
Stockholders Equity	-7.45M	-6.64M	-5.78M	-4.64M	-4.10M	-3.60M
Cash Flow
Free Cash Flow	-1.31M	-428.49K	-296.97K	-222.64K	-481.59K	61.94K
Operating Cash Flow	-1.25M	-426.69K	-296.97K	-222.64K	-426.39K	64.59K
Investing Cash Flow	-6.23K	-1.80K	0.00	850.00	-52.70K	-2.65K
Financing Cash Flow	1.39M	487.64K	293.62K	211.72K	136.75K	184.46K

PreveCeutical Medical Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.02
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:PREV, the sentiment is Negative. The current price of 0.02 is below the 20-day moving average (MA) of 0.02, below the 50-day MA of 0.02, and below the 200-day MA of 0.03, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 45.00 is Neutral, neither overbought nor oversold. The STOCH value of 66.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:PREV.

PreveCeutical Medical Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
MDMA	49 Neutral	C$13.07M	-5.97	-85.96%	―	-72.51%	-170.13%
CYBN	48 Neutral	C$1.92M	-0.02	-53.20%	―	―	33.28%
DOSE	43 Neutral	C$17.80M	-3.78	―	―	95.76%	22.56%
BETR	43 Neutral	C$6.84M	-3.38	―	―	―	62.43%
PREV	42 Neutral	C$11.74M	-3.64	21.59%	―	―	-120.00%

PreveCeutical Medical Corporate Events

PreveCeutical and BioGene Complete Strategic Spin-Off Arrangement

PreveCeutical Medical Inc. and BioGene Therapeutics Inc. have completed a plan of arrangement that involves the spin-off of 12,000,000 BioGene shares from PreveCeutical. This strategic move, approved by shareholders and the Supreme Court of British Columbia, results in PreveCeutical shareholders owning shares in both companies. BioGene will focus on developing a Dual Gene Therapy program, while PreveCeutical continues its work on preventive and curative therapies. This arrangement is expected to enhance the focus and operational efficiency of both companies, potentially strengthening their positions in the health sciences industry.

PreveCeutical Finalizes Arrangement with BioGene to Expand Market Reach

PreveCeutical Medical Inc. announced the completion of its plan of arrangement with BioGene Therapeutics Inc., effective November 24, 2025. Shareholders will receive new common shares of PreveCeutical and a portion of BioGene shares. This strategic move is expected to enhance PreveCeutical’s market position and expand its reach in the health sciences industry, potentially benefiting stakeholders by broadening the company’s therapeutic offerings.

PreveCeutical Clarifies Shareholder Arrangement with BioGene

PreveCeutical Medical Inc. announced a clarification regarding its plan of arrangement with BioGene Therapeutics Inc., specifying that shareholders of record on November 24, 2025, will receive new common shares of PreveCeutical and a fraction of BioGene shares. This announcement is significant as it impacts the company’s shareholder structure and could influence its market positioning, potentially affecting stakeholders’ interests.

PreveCeutical Completes Second Tranche of Private Placement

PreveCeutical Medical Inc. has successfully closed the second tranche of its non-brokered private placement, raising $455,000 through the issuance of 11,375,000 units at $0.04 per unit. The funds will be used for outstanding payables, operating expenses, and general working capital, potentially strengthening the company’s financial position and supporting its ongoing research and development efforts.

PreveCeutical Completes Strategic Arrangement with BioGene

PreveCeutical Medical Inc. has announced the completion of its plan of arrangement with BioGene Therapeutics Inc., which involves a share capital reorganization and the spin-out of 12,000,000 BioGene shares to PreveCeutical shareholders. This strategic move will allow PreveCeutical to continue its focus on preventive and curative therapies, while BioGene will concentrate on developing the Dual Gene Therapy program, potentially enhancing both companies’ positions in their respective fields.